Drug Approval | June 11, 2021
CSIR join hands with SUVEN Pharmaceuticals
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
Subscribe To Our Newsletter & Stay Updated
